List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/221960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	0.6	568
2	Mutant <i>GNAS</i> detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	6.1	160
3	Mutant TP53 in Duodenal Samples of Pancreatic Juice From Patients With Pancreatic Cancer or High-Grade Dysplasia. Clinical Gastroenterology and Hepatology, 2013, 11, 719-730.e5.	2.4	154
4	Modified Blumgart Anastomosis for Pancreaticojejunostomy: Technical Improvement in Matched Historical Control Study. Journal of Gastrointestinal Surgery, 2014, 18, 1108-1115.	0.9	145
5	Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6829.	1.4	121
6	Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (United States), 2016, 95, e3781.	0.4	105
7	Effectiveness of plasma treatment on pancreatic cancer cells. International Journal of Oncology, 2015, 47, 1655-1662.	1.4	98
8	Recent advances in the molecular diagnostics of gastric cancer. World Journal of Gastroenterology, 2015, 21, 9838.	1.4	92
9	Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer. Medicine (United) Tj ETQq1	1 0.784314 0.4	rgðð /Overlo
10	Pattern of Lymph Node Metastasis Spread in Pancreatic Cancer. Pancreas, 2011, 40, 951-955.	0.5	89
11	Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Molecular Carcinogenesis, 2011, 50, 571-579.	1.3	86
12	Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer, 2015, 18, 635-643.	2.7	83
13	Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. International Journal of Oncology, 2013, 43, 88-94.	1.4	81
14	Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Annals of Surgery, 2018, 267, 495-503.	2.1	81
15	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	2.4	74
16	Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. International Journal of Surgery, 2017, 39, 45-51.	1.1	74
17	Intraperitoneal Administration of Plasma-Activated Medium: Proposal of a Novel Treatment Option for Peritoneal Metastasis From Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 1188-1194.	0.7	74
18	Comparison of inflammationâ€based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 682-688.	1.4	72

#	Article	IF	CITATIONS
19	Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery, 2010, 148, 285-290.	1.0	71
20	Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer, 2014, 14, 108.	1.1	71
21	Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016, 19, 255-263.	2.7	70
22	Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis. Annals of Surgical Oncology, 2010, 17, 923-932.	0.7	69
23	Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10584.	1.4	66
24	Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas. Annals of Surgery, 2010, 251, 483-487.	2.1	65
25	Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas. Pancreas, 2011, 40, 3-9.	0.5	63
26	The Controlling Nutritional Status Score Serves as a Predictor of Short- and Long-Term Outcomes for Patients with Stage 2 or 3 Gastric Cancer: Analysis of a Multi-institutional Data Set. Annals of Surgical Oncology, 2019, 26, 456-464.	0.7	61
27	Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinicoâ€pathological parameters. Journal of Surgical Oncology, 2008, 98, 190-196.	0.8	59
28	Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures. Annals of Surgical Oncology, 2012, 19, 176-183.	0.7	58
29	Preoperative Internal Biliary Drainage Increases the Risk of Bile Juice Infection and Pancreatic Fistula After Pancreatoduodenectomy. Pancreas, 2015, 44, 465-470.	0.5	58
30	Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discovery, 2022, 12, 692-711.	7.7	58
31	SMAD4 Expression Predicts Local Spread and Treatment Failure in Resected Pancreatic Cancer. Pancreas, 2015, 44, 660-664.	0.5	57
32	Recurrence Pattern and Prognosis of Pancreatic Cancer After Pancreatic Fistula. Annals of Surgical Oncology, 2011, 18, 2329-2337.	0.7	56
33	Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine (United States), 2015, 94, e1647.	0.4	55
34	Function and diagnostic value of <scp>Anosminâ€I </scp> in gastric cancer progression. International Journal of Cancer, 2016, 138, 721-730.	2.3	55
35	SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene, 2018, 37, 5355-5366.	2.6	55
36	Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. International Journal of Surgery, 2016, 30, 136-142.	1.1	54

3

#	Article	IF	CITATIONS
37	Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. International Journal of Oncology, 2009, 35, 477-83.	1.4	53
38	Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery, 2015, 158, 1573-1580.	1.0	53
39	Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery, 2016, 159, 878-884.	1.0	53
40	Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2014, 110, 764-769.	0.8	51
41	Vein resections >3Âcm during pancreatectomy are associated withÂpoor 1-year patency rates. Surgery, 2015, 157, 708-715.	1.0	51
42	Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. Journal of Gastroenterology, 2017, 52, 81-93.	2.3	51
43	Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 887-895.	0.7	50
44	Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Letters, 2010, 289, 170-177.	3.2	49
45	Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2011, 18, 572-579.	0.7	49
46	Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 66.	3.5	49
47	Preoperative predictors of postoperative complications after gastric cancer resection. Surgery Today, 2020, 50, 3-11.	0.7	48
48	Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Molecular Cancer, 2020, 19, 131.	7.9	48
49	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. British Journal of Cancer, 2020, 122, 771-777.	2.9	48
50	Updated evidence on adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1549-1560.	1.4	47
51	Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 502-509.	0.7	46
52	Metastatic pathway-specific transcriptome analysis identifies <i>MFSD4</i> as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget, 2016, 7, 13667-13679.	0.8	46
53	The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 847-855.	1.1	45
54	Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer, 2015, 18, 288-296.	2.7	45

#	Article	IF	CITATIONS
55	Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. British Journal of Surgery, 2018, 105, 1349-1358.	0.1	44
56	Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 4303-4312.	3.2	43
57	Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Digestive Surgery, 2016, 33, 121-128.	0.6	43
58	Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World Journal of Gastroenterology, 2017, 23, 2519.	1.4	43
59	Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Molecular Cancer, 2022, 21, 42.	7.9	43
60	Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. Journal of Surgical Oncology, 2014, 110, 745-751.	0.8	42
61	Clinical Implication of Morphological Subtypes in Management of Intraductal Papillary Mucinous Neoplasm. Annals of Surgical Oncology, 2014, 21, 2444-2452.	0.7	41
62	The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surgery Today, 2014, 44, 1692-1701.	0.7	41
63	Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 44, 44-52.	1.4	41
64	The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Annals of Surgical Oncology, 2016, 23, 214-221.	0.7	41
65	Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. World Journal of Gastroenterology, 2014, 20, 8535.	1.4	41
66	Diversity of Clinical Implication of B-Cell Translocation Gene 1 Expression by Histopathologic and Anatomic Subtypes of Gastric Cancer. Digestive Diseases and Sciences, 2015, 60, 1256-1264.	1.1	40
67	Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. International Journal of Oncology, 2016, 49, 1195-1202.	1.4	40
68	Preoperative Albumin–Bilirubin Grade Predicts Recurrences After Radical Gastrectomy in Patients with pT2â€4 Gastric Cancer. World Journal of Surgery, 2018, 42, 773-781.	0.8	40
69	B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 641-648.	1.4	39
70	Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. International Journal of Cancer, 2016, 139, 2290-2298.	2.3	39
71	FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 3438-3445.	0.7	39
72	Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer, 2019, 22, 1215-1225.	2.7	39

#	Article	IF	CITATIONS
73	Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy. Surgery, 2014, 156, 601-610.	1.0	38
74	Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1934-1940.	0.7	38
75	Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 657-670.	1.4	38
76	Review of recent molecular landscape knowledge of gastric cancer. Histology and Histopathology, 2018, 33, 11-26.	0.5	38
77	Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World Journal of Gastroenterology, 2019, 25, 2743-2751.	1.4	38
78	Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Pancreas, 2018, 47, 823-829.	0.5	36
79	The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset. Digestive Surgery, 2020, 37, 135-144.	0.6	36
80	Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas, 2011, 40, 1029-1033.	0.5	35
81	Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. Annals of Surgical Oncology, 2015, 22, 3905-3912.	0.7	34
82	A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. Gastric Cancer, 2018, 21, 1014-1023.	2.7	34
83	Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. OncoTargets and Therapy, 2013, 6, 1417.	1.0	32
84	Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2083-2090.	0.7	32
85	Multiâ€institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. Cancer Medicine, 2019, 8, 5194-5201.	1.3	32
86	Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multiâ€institutional Dataset. World Journal of Surgery, 2019, 43, 870-877.	0.8	32
87	Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset. Gastric Cancer, 2019, 22, 853-863.	2.7	32
88	Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. Journal of Gastroenterology, 2015, 50, 590-600.	2.3	31
89	The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer. Gastric Cancer, 2019, 22, 1143-1152.	2.7	31
90	Clinical significance of expression and epigenetic profiling of <i>TUSC1</i> in gastric cancer. Journal of Surgical Oncology, 2014, 110, 136-144.	0.8	30

6

#	Article	IF	CITATIONS
91	Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer. Molecular Therapy - Nucleic Acids, 2020, 22, 791-802.	2.3	30
92	Significance of Preoperative Systemic Inflammation Score in Shortâ€Term and Longâ€Term Outcomes of Patients with Pathological T2–4 Gastric Cancer After Radical Gastrectomy. World Journal of Surgery, 2018, 42, 3277-3285.	0.8	29
93	Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Scientific Reports, 2018, 8, 9846.	1.6	29
94	Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer, 2020, 23, 203-211.	2.7	29
95	A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Molecular Cancer, 2022, 21, 44.	7.9	29
96	Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head. Pancreas, 2011, 40, 1258-1263.	0.5	28
97	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clinical and Translational Gastroenterology, 2014, 5, e62.	1.3	28
98	Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbeck's Archives of Surgery, 2016, 401, 1143-1152.	0.8	28
99	The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (United States), 2016, 95, e4282.	0.4	28
100	Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy. Digestive Surgery, 2018, 35, 55-63.	0.6	28
101	Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 88.	3.5	27
102	Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. Pancreas, 2016, 45, 198-203.	0.5	27
103	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery, 2017, 162, 784-791.	1.0	27
104	Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations. Annals of Surgical Oncology, 2019, 26, 3718-3726.	0.7	27
105	Pancreatic Fat and Body Composition Measurements by Computed Tomography are Associated with Pancreatic Fistula After Pancreatectomy. Annals of Surgical Oncology, 2021, 28, 530-538.	0.7	27
106	Significance of the Splenic Vein and Its Branches in Pancreatoduodenectomy with Resection of the Portal Vein System. Digestive Surgery, 2015, 32, 382-388.	0.6	26
107	NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncology Letters, 2016, 11, 1847-1854.	0.8	26
108	The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. International Journal of Oncology, 2017, 50, 381-386.	1.4	26

#	Article	IF	CITATIONS
109	Pancreatoduodenectomy With Portal Vein Resection Is Feasible and Potentially Beneficial for Elderly Patients With Pancreatic Cancer. Pancreas, 2014, 43, 951-958.	0.5	25
110	Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Annals of Surgical Oncology, 2015, 22, 1499-1507.	0.7	25
111	Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells. Oncology Reports, 2017, 38, 1760-1766.	1.2	25
112	Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncology Reports, 2014, 31, 693-700.	1.2	24
113	Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula. Pancreas, 2015, 44, 971-976.	0.5	24
114	Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. International Journal of Oncology, 2015, 47, 1811-1818.	1.4	24
115	GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer. Scientific Reports, 2017, 7, 42089.	1.6	24
116	Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surgery, 2019, 19, 143.	0.6	24
117	Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepato-Gastroenterology, 2014, 61, 1756-61.	0.5	24
118	Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10. Annals of Surgical Oncology, 2014, 21, 691-698.	0.7	23
119	Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. Journal of Surgical Oncology, 2015, 112, 381-386.	0.8	23
120	Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas, 2018, 47, 974-979.	0.5	23
121	Evaluation of MAGEâ€Ð4 expression in hepatocellular carcinoma in Japanese patients. Journal of Surgical Oncology, 2013, 108, 557-562.	0.8	22
122	Feeding Duodenostomy Decreases the Incidence of Mechanical Obstruction After Radical Esophageal Cancer Surgery. World Journal of Surgery, 2015, 39, 1105-1110.	0.8	22
123	Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 836-844.	0.7	22
124	Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 17-27.	0.8	22
125	Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer: a prospective multicenter observational study (CCOG1505). Gastric Cancer, 2019, 22, 607-616.	2.7	21
126	Expression Analysis of THOP1 in Background Liver, a Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis. Annals of Surgical Oncology, 2014, 21, 443-450.	0.7	20

#	Article	IF	CITATIONS
127	Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4353-4362.	1.3	20
128	Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncology Reports, 2014, 31, 1305-1313.	1.2	19
129	The Prognostic Relevance of Subcarinal Lymph Node Dissection in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 611-618.	0.7	19
130	Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2–4 gastric cancer. Gastric Cancer, 2017, 20, 736-743.	2.7	19
131	FBXO50 Enhances the Malignant Behavior of Gastric Cancer Cells. Annals of Surgical Oncology, 2017, 24, 3771-3779.	0.7	19
132	Expression of sushi domain containing two reflects the malignant potential of gastric cancer. Cancer Medicine, 2018, 7, 5194-5204.	1.3	19
133	Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2019, 26, 4773-4781.	0.7	19
134	Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Hpb, 2019, 21, 1211-1218.	0.1	19
135	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	1.0	18
136	Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncology Letters, 2015, 9, 1201-1206.	0.8	18
137	Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 124-136.	0.8	18
138	Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines. In Vivo, 2019, 33, 1785-1792.	0.6	18
139	Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer. International Journal of Cancer, 2020, 146, 2865-2876.	2.3	18
140	Propensity-score-matched analysis of a multi-institutional dataset to compare postoperative complications between Billroth I and Roux-en-Y reconstructions after distal gastrectomy. Gastric Cancer, 2020, 23, 734-745.	2.7	18
141	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	0.8	18
142	Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma. Anticancer Research, 2017, 37, 293-300.	0.5	18
143	Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 45, 2005-2012.	1.4	17
144	Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1453-1460.	0.7	17

#	Article	IF	CITATIONS
145	Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 532-539.	0.7	17
146	Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncology Letters, 2016, 12, 4821-4828.	0.8	17
147	Modified Blumgart Suturing Technique for Remnant Closure After Distal Pancreatectomy: a Propensity Score-Matched Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 374-384.	0.9	17
148	Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer. Clinical Cancer Research, 2021, 27, 2292-2300.	3.2	17
149	Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway. British Journal of Cancer, 2021, 124, 1449-1460.	2.9	17
150	Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. Journal of Experimental and Clinical Cancer Research, 2013, 32, 65.	3.5	16
151	Prognostic relevance of SAMSN1 expression in gastric cancer. Oncology Letters, 2016, 12, 4708-4716.	0.8	16
152	Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival. Annals of Surgical Oncology, 2019, 26, 1535-1543.	0.7	16
153	Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy. Medicine (United States), 2015, 94, e2398.	0.4	15
154	Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2015, 28, 188-195.	0.2	15
155	Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus. Oncology Letters, 2017, 14, 4822-4828.	0.8	15
156	Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer, 2017, 17, 610.	1.1	15
157	Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 725-738.	1.5	15
158	Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer. Anticancer Research, 2019, 39, 6125-6133.	0.5	15
159	Detection of indocyanine green fluorescence to determine tumor location during laparoscopic gastrectomy for gastric cancer: Results of a prospective study. Asian Journal of Endoscopic Surgery, 2020, 13, 160-167.	0.4	15
160	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Journal of Surgical Oncology, 2015, 112, 622-628.	0.8	14
161	CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 1963-1970.	1.4	14
162	S-1 plus <i>nab</i> -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	0.8	14

#	Article	IF	CITATIONS
163	Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy. Ecological Management and Restoration, 2016, 29, 598-602.	0.2	14
164	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncology Letters, 2016, 12, 3662-3668.	0.8	14
165	Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multiâ€institutional dataset. Cancer Medicine, 2018, 7, 6020-6029.	1.3	14
166	Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer. Ecological Management and Restoration, 2020, 33, .	0.2	14
167	Optimized Cutoff Value of Serum Squamous Cell Carcinoma Antigen Concentration Accurately Predicts Recurrence After Curative Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2020, 27, 1233-1240.	0.7	14
168	Emerging evidence of molecular biomarkers in hepatocellular carcinoma. Histology and Histopathology, 2018, 33, 343-355.	0.5	14
169	MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer. Oncology Letters, 2020, 20, 1-1.	0.8	14
170	Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer, 2022, 25, 558-572.	2.7	14
171	Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75Åyears of age with metastatic colorectal cancer. BMC Cancer, 2015, 15, 786.	1.1	13
172	The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer, 2017, 17, 243.	1.1	13
173	PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 2071-2080.	0.7	13
174	C-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer. British Journal of Cancer, 2021, 125, 220-228.	2.9	13
175	Hepatectomy for hepatocellular carcinoma in patients with hemophilia. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 824-828.	1.4	12
176	A resected case of symptomatic acinar cell cystadenoma of the pancreas displacing the main pancreatic duct. Surgical Case Reports, 2016, 2, 39.	0.2	12
177	Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. Diseases of the Colon and Rectum, 2018, 61, 461-471.	0.7	12
178	Pattern-Specific Transcriptomics Identifies <i>ASGR2</i> as a Predictor of Hematogenous Recurrence of Gastric Cancer. Molecular Cancer Research, 2018, 16, 1420-1429.	1.5	12
179	Comparison of nonâ€invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. Hepatology Research, 2019, 49, 1305-1315.	1.8	12
180	Perioperative and prognostic implication of albuminâ€bilirubinâ€ <scp>TNM</scp> score in Childâ€Pugh class A hepatocellular carcinoma. Annals of Gastroenterological Surgery, 2019, 3, 65-74.	1.2	12

#	Article	IF	CITATIONS
181	Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 2081-2089.	0.7	12
182	Systemic Inflammation Score as a Predictor of Pneumonia after Radical Resection of Gastric Cancer: Analysis of a Multi-Institutional Dataset. Digestive Surgery, 2020, 37, 401-410.	0.6	12
183	Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Anticancer Research, 2020, 40, 1843-1853.	0.5	12
184	Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. Oncogene, 2021, 40, 5495-5504.	2.6	12
185	Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers, 2021, 13, 36.	1.7	12
186	Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy. Journal of Gastric Cancer, 2019, 19, 183.	0.9	12
187	Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 2546-2554.	1.4	11
188	Serosal Invasion Strongly Associated With Recurrence After Curative Hepatic Resection of Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e602.	0.4	11
189	Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1253-1261.	1.1	11
190	Copineï;½5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma. Oncology Reports, 2018, 40, 3772-3780.	1.2	11
191	Incorporating molecular biomarkers into clinical practice for gastric cancer. Expert Review of Anticancer Therapy, 2019, 19, 757-771.	1.1	11
192	KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2559-2568.	0.7	11
193	Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3195-3205.	0.7	11
194	miR-23b-3p Plays an Oncogenic Role in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 3416-3426.	0.7	11
195	Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2277-2286.	0.7	11
196	Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer. Pancreatology, 2011, 11, 68-75.	0.5	10
197	Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. Journal of Surgical Research, 2015, 195, 444-453.	0.8	10
198	Combination of continuous paravertebral block and epidural anesthesia in postoperative pain control after esophagectomy. Esophagus, 2016, 13, 42-47.	1.0	10

#	Article	IF	CITATIONS
199	ASO Author Reflections: Troponin I2—A Specific Biomarker for Detection and Prediction of Peritoneal Metastasis in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 709-710.	0.7	10
200	A novel dualâ€marker expression panel for easy and accurate risk stratification of patients with gastric cancer. Cancer Medicine, 2018, 7, 2463-2471.	1.3	10
201	Short-term outcomes after conventional transthoracic esophagectomy. Nagoya Journal of Medical Science, 2016, 78, 69-78.	0.6	10
202	Operative Treatment of Thrombotic Occlusion of the Portal Vein Immediately After Pancreatectomy With Portal Vein Resection. Pancreas, 2010, 39, 265-266.	0.5	9
203	<i>PRAME</i> Expression as a Potential Biomarker for Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 5943-5951.	0.5	9
204	Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer. Anticancer Research, 2019, 39, 5903-5910.	0.5	9
205	STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer. Cancer Genomics and Proteomics, 2020, 17, 509-516.	1.0	9
206	AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer. Anticancer Research, 2020, 40, 6713-6721.	0.5	9
207	Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3247-3256.	0.7	9
208	Association between Lymphovascular Invasion and Recurrence in Patients with pT1N+ or pT2–3N0 Gastric Cancer: a Multi-institutional Dataset Analysis. Journal of Gastric Cancer, 2020, 20, 41.	0.9	9
209	D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Surgery Today, 2020, 50, 1434-1442.	0.7	9
210	Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. Oncology Reports, 2021, 47, .	1.2	9
211	Preservation of the Pyloric Ring Confers Little Benefit in Patients Undergoing Total Pancreatectomy. World Journal of Surgery, 2014, 38, 1807-1813.	0.8	8
212	High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncology Reports, 2015, 33, 767-773.	1.2	8
213	Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Pancreas, 2018, 47, 1350-1356.	0.5	8
214	Accurate Risk Stratification of Patients with Nodeâ€Positive Gastric Cancer by Lymph Node Ratio. World Journal of Surgery, 2020, 44, 4184-4192.	0.8	8
215	Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas, 2020, 49, 699-705.	0.5	8
216	Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget, 2018, 9, 18775-18785.	0.8	8

#	Article	IF	CITATIONS
217	Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. Journal of Clinical Medicine, 2021, 10, 5666.	1.0	8
218	The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 546-553.	0.7	7
219	Nutritional Recovery after Open and Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Prospective Multicenter Comparative Trial (CCOG1204). Digestive Surgery, 2018, 35, 11-18.	0.6	7
220	Optical trocar access for initial trocar placement in laparoscopic gastrointestinal surgery: <scp>A</scp> propensity scoreâ€matching analysis. Asian Journal of Endoscopic Surgery, 2019, 12, 37-42.	0.4	7
221	An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Oncologist, 2020, 25, e1650-e1654.	1.9	7
222	Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 4639-4646.	0.5	7
223	ls the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?. World Journal of Gastroenterology, 2020, 26, 1594-1600.	1.4	7
224	Prognostic Value of a Modified Albumin–Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, 29, 4889-4896.	0.7	7
225	Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncology Letters, 2017, 13, 4334-4340.	0.8	6
226	Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of Sâ€1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multiâ€Institutional Dataset Analysis. World Journal of Surgery, 2019, 43, 2016-2024.	0.8	6
227	Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II). International Journal of Clinical Oncology, 2020, 25, 118-125.	1.0	6
228	Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer. Cancer Medicine, 2020, 9, 5392-5399.	1.3	6
229	Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 391-400.	1.0	6
230	High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences. Nutrition and Cancer, 2021, 73, 996-1003.	0.9	6
231	Accurate Prediction of Prognosis After Radical Resection of Gastric Cancer by the Modified Systemic Inflammation Score; a Multicenter Dataset Analysis. World Journal of Surgery, 2021, 45, 2513-2520.	0.8	6
232	Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 578-585.	0.7	6
233	Method of Bilateral Pleural Drainage by Single Blake Drain After Esophagectomy. World Journal of Surgery, 2015, 39, 727-731.	0.8	5
234	Modified twoâ€dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Science, 2016, 107, 1492-1498.	1.7	5

#	Article	IF	CITATIONS
235	Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). International Journal of Clinical Oncology, 2017, 22, 1052-1059.	1.0	5
236	Expression, Function, and Prognostic Value of MAGE-D4 Protein in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 6015-6023.	0.5	5
237	Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. Oncology, 2020, 98, 48-52.	0.9	5
238	Tissue <i>RNFT2</i> Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer. Anticancer Research, 2021, 41, 609-617.	0.5	5
239	Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer Journal of Clinical Oncology, 2014, 32, 302-302.	0.8	5
240	A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 829-838.	1.1	4
241	Tumor size  ≥50Âmm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative Sâ€IÂMonotherapy: Analysis of a Multiâ€institution Dataset. World Journal of Surgery, 2020, 44, 194-201.	0.8	4
242	Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database. Surgery Today, 2021, 51, 821-828.	0.7	4
243	An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 71070-71079.	0.8	4
244	Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2281-2285.	0.5	4
245	Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer. International Journal of Oncology, 2022, 60, .	1.4	4
246	Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2016, 29, 663-669.	0.2	3
247	RASEF expression correlates with hormone receptor status in breast cancer. Oncology Letters, 2018, 16, 7223-7230.	0.8	3
248	Cutting-edge evidence of adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1109-1122.	1.4	3
249	Randomised phase II trial of capecitabine plus oxaliplatinÂwith continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). European Journal of Cancer, 2021, 144, 61-71.	1.3	3
250	Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer. Histology and Histopathology, 2021, 36, 817-832.	0.5	3
251	Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Current Oncology, 2021, 28, 4080-4092.	0.9	3
252	<editors' choice=""> Efficacy of enteral nutrients containing β-hydroxy-β-methylbutyrate, glutamine, and arginine for the patients with anastomotic leakage after gastrectomy: study protocol of a multicenter phase II clinical trial. Nagoya Journal of Medical Science, 2018, 80, 351-355.</editors'>	0.6	3

MITSURO KANDA

#	Article	IF	CITATIONS
253	SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2699-2709.	0.7	3
254	A Vascular Endothelial Growth Factor Gene Polymorphism Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasm. Pancreas, 2015, 44, 608-614.	0.5	2
255	Prognosis After Laparoscopic Gastrectomy in Patients with Pathological Stage II or III Gastric Cancer Who Were Preoperatively Diagnosed with Clinical Stage I: Propensity Score Matching Analysis of a Multicenter Dataset. Annals of Surgical Oncology, 2020, 27, 268-275.	0.7	2
256	Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus. Surgery Today, 2021, 51, 153-158.	0.7	2
257	Efficacy of Splenectomy for Proximal Gastric Cancer with Greater Curvature Invasion or Type 4 Tumor: a Propensity Score Analysis of a Multiâ€Institutional Dataset. World Journal of Surgery, 2021, 45, 2840-2848.	0.8	2
258	Prognostic impact of a microscopic positive margin in patients undergoing gastrectomy for gastric cancer: a propensity score‑matched analysis of a multi‑institutional dataset. Surgery Today, 2022, 52, 559-566.	0.7	2
259	E-PASS scoring system serves as a predictor of short- and long-term outcomes in gastric cancer surgery. Surgery Today, 2022, 52, 914-922.	0.7	2
260	Intraductal Papillary Mucinous Carcinoma with Portal Annular Pancreas Anomaly Treated by Middle-preserving Pancreatectomy. Japanese Journal of Gastroenterological Surgery, 2015, 48, 706-714.	0.0	2
261	Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. Journal of Gastroenterology, 2022, 57, 640-653.	2.3	2
262	Preoperative neutrophil-to-platelet ratio as a potential prognostic factor for gastric cancer with positive peritoneal lavage cytology in the absence of other non-curative factors: a multi-institutional dataset analysis. Surgery Today, 2023, 53, 198-206.	0.7	2
263	Operative Treatment of Pancreatic Ductal Adenocarcinoma With Extensive Portal Venous Tumor Embolism. Pancreas, 2010, 39, 268-269.	0.5	1
264	Stapling an extracorporeal Billrothâ€l anastomosis by the complete double stapling technique after laparoscopyâ€assisted distal gastrectomy. Asian Journal of Endoscopic Surgery, 2017, 10, 137-142.	0.4	1
265	ASO Author Reflections: Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival. Annals of Surgical Oncology, 2019, 26, 596-597.	0.7	1
266	Clinical impact of additional therapy for residual pancreatic cancer. Surgery Today, 2020, 50, 440-448.	0.7	1
267	Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Clinical Epigenetics, 2021, 13, 172.	1.8	1
268	Clinical features of colorectal mucinous and poorly differentiated adenocarcinomas; study concept of a propensity score analysis in a pooled data of 5530 patients. Annals of Cancer Research and Therapy, 2016, 24, 52-53.	0.1	1
269	Abstract 3831: Clinical significance of SMAD4 expression in resectable pancreatic cancer: correlation with tumor progression and recurrence pattern. , 2014, , .		1
270	Abstract 1148: Epithelial to mesenchymal transition might be induced via CD44 isoform switch in		1

colorectal cancer. , 2014, , .

#	Article	IF	CITATIONS
271	ASO Visual Abstract: Prognostic Value of a Modified Albumin–Bilirubin Grade Designed for Patients with Esophageal Squamous Cell Carcinoma after Radical Resection. Annals of Surgical Oncology, 2022, , 1.	0.7	1
272	ASO Author Reflections: Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 592-593.	0.7	0
273	ASO Author Reflections: Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3206-3207.	0.7	0
274	ASO Author Reflections: KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2569-2570.	0.7	0
275	ASO Author Reflections: Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3257-3258.	0.7	Ο
276	Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Pancreas, 2021, 50, 37-46.	0.5	0
277	Abstract 1733: Fibulin 1 is a novel tumor suppressor gene detected in hepatocellular carcinoma using a double combination array analysis. , 2010, , .		Ο
278	Abstract 4660: Double combination array analysis detected A kinase anchor protein 12 (AKAP12) gene as a new tumor suppressor gene of hepatocellular carcinoma. , 2010, , .		0
279	Abstract 1750: Reduced xpression of Reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. , 2010, , .		0
280	Abstract 3539: A study ofTHOP1, a predictive factor of prognosis in HCC, by multi-array analysis of background liver , 2013, , .		0
281	Overexpression of melanoma-associated antigen D4 as an independent prognostic factor in squamous cell carcinoma of the esophagus Journal of Clinical Oncology, 2014, 32, 71-71.	0.8	0
282	Risk factors that affect continuation of S-1 chemotherapy as an adjuvant setting after radical gastrectomy for gastric cancer Journal of Clinical Oncology, 2014, 32, 151-151.	0.8	0
283	Response to the first-line FOLFOX plus bevacizumab (BEV) therapy to predict responses to the subsequent therapies and survival in the BEV beyond progression (BBP) strategy for metastatic colorectal cancer: A retrospective analysis of CCOG-0801 study Journal of Clinical Oncology, 2014, 32, 428-428.	0.8	Ο
284	Reduced expression of DENND2D through promoter hypermethylation as an adverse prognostic factor in squamous cell carcinoma of the esophagus Journal of Clinical Oncology, 2014, 32, 58-58.	0.8	0
285	The impact of dose reduction and time delay in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer Journal of Clinical Oncology, 2014, 32, 631-631.	0.8	0
286	Abstract 2870: ZGPAT gene expression in non-tumor hepatocellular carcinoma tissue is a likely biomarker for survival risk. , 2014, , .		0
287	Abstract 3822: Correlation between worse prognosis and lower expression of theTPPPgene in patients with hepatocellular carcinoma, detected by multiarray analysis. , 2014, , .		0
288	Abstract 4717: Detection of the Cyclin J (CCNJ) as a new cancer-related gene in human hepatocellular carcinoma by using a method of triple combination array analysis. , 2014, , .		0

#	Article	IF	CITATIONS
289	Abstract 3816: Correlation between worse prognosis and higher expression of theJAK2gene in corresponding non-neoplastic tissue in patients with hepatocellular carcinoma, extracted by multiarray analysis. , 2014, , .		0
290	Abstract 3423: Expression level of inflammasomes compornents NLRP3, NLRC4, and CASP1 in background non tumorous tissue were associated with worse prognosis for curatively resected hepatocellular carcinoma. , 2015, , .		0
291	Abstract 4101: Clinical significance of ZEB1 mRNA levels in peritoneal washing for gastric cancer. , 2015, , .		0
292	Abstract 3422: Alteration of aldo-keto reductase family 1, member B10 (AKR1B10) expression among tumor and background non-tumorous tissue of curatively resected hepatocellular carcinoma is associated with worse prognosis. , 2015, , .		0
293	Abstract 4253: A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm. , 2015, , .		0
294	A prospective trial to evaluate treatment effects of a β-hydroxy-β-methylbutyrate containing nutrient for leakage at the anastomotic site after esophagectomy. Nagoya Journal of Medical Science, 2020, 82, 33-37.	0.6	0
295	Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemporary Clinical Trials Communications, 2021, 24, 100853.	0.5	0
296	ASO Visual Abstract: SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2710.	0.7	0
297	Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection. World Journal of Surgery, 2022, 46, 648-655.	0.8	0
298	ASO Author Reflections: Optimized Cutoff Value of Albumin–Bilirubin Score to Predict Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, , 1.	0.7	0